06.29.15
Jeffrey H. Hanke, Ph.D., has been appointed to the newly created role of executive vice president, R&D, and chief scientific officer at Tesaro. Dr. Hanke will oversee non-clinical R&D organizations, as well as program management. He reports to Mary Lynne Hedley, Ph.D., president and chief operating officer of TESARO.
Dr. Hanke has more than 25 years of experience in biopharmaceutical R&D. Most recently he served as senior vice president, Research, and Global head of Biotherapeutics at Boehringer Ingelheim, Inc. Previously he served as vice president of Cancer Research at AstraZeneca, where he was responsible for building and leading the U.S. cancer research organization and establishing a portfolio of product candidates. He also served in several roles of increasing responsibility within the R&D organization at Pfizer, where he led teams in the areas of immunology, inflammation, allergy/respiratory, and oncology.
"Jeff is a great addition to the TESARO executive team," said Mary Lynne Hedley. "He brings to TESARO strong leadership skills, a successful track record in overseeing multiple oncology programs, and a wealth of experience in building R&D organizations. Jeff's deep expertise in immunology and oncology will be invaluable to TESARO as we continue to advance our portfolio of product candidates."
Dr. Hanke has more than 25 years of experience in biopharmaceutical R&D. Most recently he served as senior vice president, Research, and Global head of Biotherapeutics at Boehringer Ingelheim, Inc. Previously he served as vice president of Cancer Research at AstraZeneca, where he was responsible for building and leading the U.S. cancer research organization and establishing a portfolio of product candidates. He also served in several roles of increasing responsibility within the R&D organization at Pfizer, where he led teams in the areas of immunology, inflammation, allergy/respiratory, and oncology.
"Jeff is a great addition to the TESARO executive team," said Mary Lynne Hedley. "He brings to TESARO strong leadership skills, a successful track record in overseeing multiple oncology programs, and a wealth of experience in building R&D organizations. Jeff's deep expertise in immunology and oncology will be invaluable to TESARO as we continue to advance our portfolio of product candidates."